Design, Synthesis and Biological Evaluation of Some Triazole Schiff’s Base Derivatives as Potential Antitubercular Agents
Authors:
Open Access
- 30 April 2018
- journal article
- Published by Bentham Science Publishers Ltd. in The Open Medicinal Chemistry Journal
- Vol. 12 (1) , 48-59
Abstract
Background: Tuberculosis (TB) is the second important cause of death worldwide caused by a bacterium calledMycobacterium tuberculosis. There is a need to find and develop new Anti-TB medications that are effective, inexpensive and suitable with human immunodeficiency virus and other anti-TB drugs used in many countries and mainly the developing countries where the disease is widespread. These drugs must be designed to shorten treatment time and to be active against resistant forms of the mycobacteria that will help to increase the patients compliance. A key compound which could be used as a lead to meet these requirements, is the thiolactomycin (TLM). This antibiotic which is naturally available has an ability to treatM. tuberculosisby inhibiting condensing enzymes called FAS II (mtFabH, KasA and KasB) which are related to biosynthesis of mycolic acid.Methods: Our main aims are to design and synthesize analogues of TLM as new lead molecules which could be a possible anti–TB candidate. To overcome the synthetic challenges associated with preparing the chiral TLM analogues; we synthesized and investigated a series of triazole analogues as inhibitors of KasA enzyme and the whole cellMycobacteria. A series of twelve compounds were synthesized, purified and fully characterized using several spectroscopic techniques. Molecular modelling studies for our synthesised compounds were achieved by using a modelling program called AutoDock 4.2 utilising rigid docking.Results: Our results indicate that analogues of TLM show a good activity as compared to TLM.Conclusion: The activity obtained for the synthesized compounds againstMycobacteria tuberculosisindicate that the synthesised compounds1,2,6and9are pharmacologically active as they restrained the growth of theMycobacteriabacteria.Keywords
This publication has 27 references indexed in Scilit:
- Thiolactomycin-based β-Ketoacyl-AcpM Synthase A (KasA) InhibitorsJournal of Biological Chemistry, 2013
- Immunological Mechanisms by Which Concomitant Helminth Infections Predispose to the Development of Human TuberculosisThe Korean Journal of Parasitology, 2012
- Recent advances in antitubercular natural productsEuropean Journal of Medicinal Chemistry, 2012
- Direct Visualization by Cryo-EM of the Mycobacterial Capsular Layer: A Labile Structure Containing ESX-1-Secreted ProteinsPLOS Pathogens, 2010
- Slow Onset Inhibition of Bacterial β-Ketoacyl-acyl Carrier Protein Synthases by ThiolactomycinJournal of Biological Chemistry, 2010
- Preparation and antitubercular activities in vitro and in vivo of novel Schiff bases of isoniazidEuropean Journal of Medicinal Chemistry, 2009
- Crystal Structures of Mycobacterium tuberculosis KasA Show Mode of Action within Cell Wall Biosynthesis and its Inhibition by ThiolactomycinStructure, 2009
- Deletion of kasB in Mycobacterium tuberculosis causes loss of acid-fastness and subclinical latent tuberculosis in immunocompetent miceProceedings of the National Academy of Sciences, 2007
- Design and synthesis of antituberculars: preparation and evaluation against Mycobacterium tuberculosis of an isoniazid Schiff baseJournal of Antimicrobial Chemotherapy, 2004
- Thiolactomycin and Related Analogues as Novel Anti-mycobacterial Agents Targeting KasA and KasB Condensing Enzymes inMycobacterium tuberculosisJournal of Biological Chemistry, 2000